Tc-99m Sestamibi and Other Agents in the Detection of Metastatic Medullary Carcinoma of the Thyroid
- 1 August 1993
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 18 (8) , 657-660
- https://doi.org/10.1097/00003072-199308000-00005
Abstract
The 10-year survival rate for medullary carcinoma of the thyroid (MCT) is 50%; thus, good tumor-seeking radiopharmaceuticals are needed to localize foci of recurrence and metastasis during follow-up. Two patients with metastatic MCT were studied with Tl-201, l-131 MIBG, Tc-99m (V)-DMSA, and Tc-99m MIBI. A SPECT study with the latter agent allowed the visualization and precise localization of a metastatic mediastinal lymph node. More studies need to be done to evaluate the role of Tc-99m MIBI in the detection of recurrence and metastases of MCT.Keywords
This publication has 0 references indexed in Scilit: